GDTC Stock Valuation & Analysis

Stock Screener

Valuator

Education

Pricing

Community

Home

Stock Screener

Valuator

Education

Pricing

Community

Institutional-grade investment tools for everyone. Built in Sweden.

Platform

Stock Screener

Valuator

Investment Score

Community

Education

Company

About

Pricing

Contact

Legal

Cookie Policy

Stock Screener

Valuator

Education

Pricing

Community

Home

Stock Screener

Valuator

Education

Pricing

Community

CytoMed Therapeutics Limited

NASDAQ

GDTC

Last Price

US $0.889

KEY FIGURES

MKT CAP

$10.5M

EPS

TTM

EPS Growth (1Y)

54.55%

PEG

TTM

P/E

TTM

P/S

TTM

YIELD

GROWTH (5Y CAGR)

Revenue

EBITDA

Base valuations

Base Cash Flow Valuation (DCF)

Fair Value

N/A

Market $0.889

—

Default assumptions

Base EBITDA Valuation

Fair Value

N/A

Market $0.889

—

Default assumptions

Base Earnings Fair Value

NOT_AVAILABLE

NOT_AVAILABLE/NOT_AVAILABLE

Valuation

NOT_AVAILABLE/NOT_AVAILABLE

Financial

NOT_AVAILABLE/NOT_AVAILABLE

Performance

—

Fin

—

Fin

—

Fin

—

Fin

—

Fin

—

Fin

—

Fin

—

Fin

—

Perf

—

Perf

—

Perf

—

Perf

—

Perf

—

Perf

—

Perf

—

Perf

—

Perf

—

Perf

—

Perf

—

Perf

—

Val

—

Val

—

Val

—

Val

—

Val

—

Val

—

Val

—

Val

Performance & Financial Health

Profit margin

Current Ratio

Capital Returns

-91.37%

Return on equity

ROIC: -97.86%

Valuation History

Price to Earnings

EV/EBITDA: -2.7X

Cash flow

Profit margin

Institutional-grade investment tools for everyone. Built in Sweden.

Platform

Stock Screener

Valuator

Investment Score

Community

Education

Company

About

Pricing

Contact

Legal

Cookie Policy

CytoMed Therapeutics Limited

NASDAQ

GDTC

Last Price

US $0.889

KEY FIGURES

MKT CAP

$10.5M

EPS

TTM

EPS Growth (1Y)

54.55%

PEG

TTM

P/E

TTM

P/S

TTM

YIELD

GROWTH (5Y CAGR)

Revenue

EBITDA

Base valuations

Base Cash Flow Valuation (DCF)

Fair Value

N/A

Market $0.889

—

Default assumptions

Base EBITDA Valuation

Fair Value

N/A

Market $0.889

—

Default assumptions

Base Earnings Fair Value

NOT_AVAILABLE

NOT_AVAILABLE/NOT_AVAILABLE

Valuation

NOT_AVAILABLE/NOT_AVAILABLE

Financial

NOT_AVAILABLE/NOT_AVAILABLE

Performance

—

Fin

—

Fin

—

Fin

—

Fin

—

Fin

—

Fin

—

Fin

—

Fin

—

Perf

—

Perf

—

Perf

—

Perf

—

Perf

—

Perf

—

Perf

—

Perf

—

Perf

—

Perf

—

Perf

—

Perf

—

Val

—

Val

—

Val

—

Val

—

Val

—

Val

—

Val

—

Val

Performance & Financial Health

Profit margin

Current Ratio

Capital Returns

-91.37%

Return on equity

ROIC: -97.86%

Valuation History

Price to Earnings

EV/EBITDA: -2.7X

Cash flow

Profit margin